VYNE THERAPEUTICS INC.

Analyst Reco. VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
0.5596 ^USD	+0.48%		-1.15%	-3.53%

Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

Analyst Reco.

25-07-31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
24-11-18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
23-05-12	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
23-03-14	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT
22-08-10	HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating	MT
21-12-06	HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target	MT
21-08-13	VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating	MT
21-05-07	VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating	MT
21-03-08	VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Rankings

Rankings

Currency / Forex

Currencies & Forex

Commodities

Cryptocurrencies

Cryptocurrencies

Interest Rates

Interest Rates Area

Stock markets for all

100% Free Registration

100% Free Registration